PM
Prosight Management Portfolio holdings
AUM
$410M
This Quarter Return
+37.02%
1 Year Return
-14.96%
3 Year Return
+21.81%
5 Year Return
+1.17%
10 Year Return
–
AUM
$219M
AUM Growth
+$219M
(+22%)
Cap. Flow
-$10.4M
Cap. Flow
% of AUM
-4.76%
Top 10 Holdings %
Top 10 Hldgs %
60.99%
Holding
47
New
12
Increased
12
Reduced
11
Closed
10
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$7.49M |
| 2 |
Envista
NVST
|
$4.89M |
| 3 |
AnaptysBio
ANAB
|
$3.82M |
| 4 |
Aldeyra Therapeutics
ALDX
|
$3.71M |
| 5 |
MeiraGTx Holdings
MGTX
|
$3.6M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.1M |
| 2 |
HNGR
Hanger Inc.
HNGR
|
$8.05M |
| 3 |
uniQure
QURE
|
$6.56M |
| 4 |
UroGen Pharma
URGN
|
$3.59M |
| 5 |
Humana
HUM
|
$3.07M |
Sector Composition
| 1 | Healthcare | 98.09% |
| 2 | Industrials | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cigna
CI
$80.2B
| $2.31M | 1.01% |
11,293
+293
| +3% | +$59.9K |
|
|
MTEM
27
DELISTED
Molecular Templates, Inc.
MTEM
| $2.25M | 0.99% |
160,883
-62,111
| -28% | -$868K |
|
28
Cue Biopharma
CUE
$60.9M
| $2.19M | 0.96% |
+137,628
| New | +$2.19M |
|
|
PRTK
29
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.81M | 0.8% |
+450,000
| New | +$1.81M |
|
30
TriNet
TNET
$3.46B
| $1.59M | 0.7% |
+28,104
| New | +$1.59M |
|
31
Kezar Life Sciences
KZR
$28.5M
| $1.28M | 0.56% |
+320,000
| New | +$1.28M |
|
|
TLGT
32
DELISTED
Teligent, Inc
TLGT
| $632K | 0.28% |
1,484,527
-961,516
| -39% | -$409K |
|
33
Milestone Pharmaceuticals
MIST
$151M
| $616K | 0.27% |
+38,481
| New | +$616K |
|
|
34
Bristol-Myers Squibb
BMY
$96.7B
| $520K | 0.23% |
8,100
-296,800
| -97% | -$19.1M |
|
|
APEN
35
DELISTED
Apollo Endosurgery, Inc.
APEN
| $454K | 0.2% |
+159,336
| New | +$454K |
|
|
UROV
36
DELISTED
Urovant Sciences Ltd.
UROV
| – | – |
-102,657
| Closed | -$972K |
|
|
SRRA
37
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-2,366,707
| Closed | -$924K |
|
|
HNGR
38
DELISTED
Hanger Inc.
HNGR
| – | – |
-395,000
| Closed | -$8.05M |
|
|
CLVS
39
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-587,626
| Closed | -$2.31M |
|
40
Q32 Bio
QTTB
$20.9M
| – | – |
-153,303
| Closed | -$2.78M |
|
41
Tempest Therapeutics
TPST
$46.6M
| – | – |
-52,051
| Closed | -$370K |
|
|
42
Humana
HUM
$37.5B
| – | – |
-12,000
| Closed | -$3.07M |
|
43
Guardant Health
GH
$8.11B
| – | – |
-41,700
| Closed | -$2.66M |
|
44
Axsome Therapeutics
AXSM
$6.09B
| – | – |
0
| – | – |
|
|
ALLK
45
DELISTED
Allakos
ALLK
| – | – |
0
| – | – |
|
46
ADMA Biologics
ADMA
$4.03B
| – | – |
-548,409
| Closed | -$2.44M |
|
47
AbbVie
ABBV
$374B
| – | – |
-39,000
| Closed | -$2.95M |
|